Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced that it will release its financial results for fiscal year 2022 and provide a business update on Monday, February 27, 2023.
| Company to host conference call and webcast at 8:30 a.m. EST. CARMIEL, Israel, Feb. 21, 2023 /PRNewswire/ -- Protalix Biotherapeutics, Inc., (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for fiscal year 2022 and provide a business update on Monday, February 27, 2023. 
The Company’s Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Details: Date: Monday, February 27, 2023 Time: 8:30 a.m. Eastern Standard Time (EST) Toll Free (U.S.): 1-877-423-9813 International: 1-201-689-8573 Conference ID: 13736250 Webcast Details: The conference will be webcast live from the Company’s website and will be available via the following links: Company Link: https://protalixbiotherapeutics.gcs-web.com/events0 Webcast Link: Registration – https://tinyurl.com/5n6rtnhw Conference ID: 13736250 Please access the websites at least 15 minutes ahead of the conference to register, download and install any necessary audio software. The conference call will be available for replay for two weeks on the Events Calendar of the Investors section of the Company’s website, at the above link. About Protalix BioTherapeutics, Inc. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix’s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human α–Galactosidase–A protein for the treatment of Fabry disease; PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs–related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa. Investor Contact Chuck Padala, Managing Director Logo: https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
SOURCE Protalix Biotherapeutics Inc. | ||
Company Codes: AMEX:PLX, TelAviv:PLX |
View original content:
